$40,000 of CASTLE BIOSCIENCES INC. lobbying was just disclosed, from Q1 of 2026, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Issues relating to Medicare coverage for laboratory diagnostic services."
You can find more data on corporate lobbying on Quiver Quantitative.
CSTL Insider Trading Activity
CSTL insiders have traded $CSTL stock on the open market 56 times in the past 6 months. Of those trades, 0 have been purchases and 56 have been sales.
Here’s a breakdown of recent trading of $CSTL stock by insiders over the last 6 months:
- DEREK J MAETZOLD (Pres. & Chief Exec. Officer) has made 0 purchases and 41 sales selling 172,231 shares for an estimated $5,287,058.
- KRISTEN M OELSCHLAGER (Chief Operating Officer) has made 0 purchases and 3 sales selling 46,498 shares for an estimated $1,567,262.
- TOBIN W JUVENAL (Chief Commercial Officer) has made 0 purchases and 5 sales selling 39,456 shares for an estimated $1,213,070.
- FRANK STOKES (Chief Financial Officer) has made 0 purchases and 5 sales selling 22,885 shares for an estimated $717,367.
- G BRADLEY COLE has made 0 purchases and 2 sales selling 7,403 shares for an estimated $210,727.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
CSTL Hedge Fund Activity
We have seen 101 institutional investors add shares of CSTL stock to their portfolio, and 85 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- RTW INVESTMENTS, LP added 2,115,237 shares (+inf%) to their portfolio in Q4 2025, for an estimated $82,282,719
- SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC added 658,725 shares (+164.7%) to their portfolio in Q4 2025, for an estimated $25,624,402
- BRAIDWELL LP removed 645,552 shares (-78.5%) from their portfolio in Q4 2025, for an estimated $25,111,972
- NUVEEN, LLC removed 432,400 shares (-45.2%) from their portfolio in Q4 2025, for an estimated $16,820,360
- DIMENSIONAL FUND ADVISORS LP removed 330,290 shares (-22.4%) from their portfolio in Q4 2025, for an estimated $12,848,281
- PARKMAN HEALTHCARE PARTNERS LLC removed 325,010 shares (-68.3%) from their portfolio in Q4 2025, for an estimated $12,642,889
- EVENTIDE ASSET MANAGEMENT, LLC added 305,000 shares (+inf%) to their portfolio in Q4 2025, for an estimated $11,864,500
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
CSTL Analyst Ratings
Wall Street analysts have issued reports on $CSTL in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Lake Street issued a "Buy" rating on 01/12/2026
- Canaccord Genuity issued a "Buy" rating on 12/22/2025
- BTIG issued a "Buy" rating on 11/05/2025
- Baird issued a "Outperform" rating on 11/04/2025
To track analyst ratings and price targets for CSTL, check out Quiver Quantitative's $CSTL forecast page.
CSTL Price Targets
Multiple analysts have issued price targets for $CSTL recently. We have seen 5 analysts offer price targets for $CSTL in the last 6 months, with a median target of $50.0.
Here are some recent targets:
- Catherine Ramsey from Baird set a target price of $44.0 on 02/27/2026
- Subbu Nambi from Guggenheim set a target price of $47.0 on 01/26/2026
- Thomas Flaten from Lake Street set a target price of $52.0 on 01/12/2026
- Kyle Mikson from Canaccord Genuity set a target price of $50.0 on 12/22/2025
- Mark Massaro from BTIG set a target price of $50.0 on 12/12/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
